Early results show safety, CSF penetration and PK clarity

First participant enrolled in EquilibriX S study

Study shows reversible switch for targeted cytokine delivery

Agency clarifies UK pathway for emerging therapies

Priority review granted for first‑in‑class Tourette therapy

First guidance for a licensed hyperhidrosis treatment

Company receives USD 10 million upfront

Partnership expands access to men’s health treatment

Saffron trial delivers positive results

Phase 3 study shows strong efficacy